Alpha 2.0
Login Register
» Authors » Erin R Aho

Erin R Aho

Explore the profile of Erin R Aho including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 255
Followers 0
Related Specialties
Biochemistry
Chemistry
Biology
Top 10 Co-Authors
William P Tansey
Stephen W Fesik
Lance R Thomas
Bin Zhao
J Grace Shaw
Shaun R Stauffer
Jonathan D Macdonald
April M Weissmiller
Feng Wang
Claudia M Nicolae
Published In
Nucleic Acids Res
J Med Chem
J Biol Chem
Epigenet Insights
Cell Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
WDR5 is a conserved regulator of protein synthesis gene expression
Bryan A, Wang J, Howard G, Guarnaccia A, Woodley C, Aho E, et al.
Nucleic Acids Res . 2020 Jan; 48(6):2924-2941. PMID: 31996893
WDR5 is a highly-conserved nuclear protein that performs multiple scaffolding functions in the context of chromatin. WDR5 is also a promising target for pharmacological inhibition in cancer, with small molecule...
2.
Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core
Tian J, Teuscher K, Aho E, Alvarado J, Mills J, Meyers K, et al.
J Med Chem . 2019 Dec; 63(2):656-675. PMID: 31858797
WD repeat domain 5 (WDR5) is a member of the WD40-repeat protein family that plays a critical role in multiple chromatin-centric processes. Overexpression of WDR5 correlates with a poor clinical...
3.
Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction
Macdonald J, Chacon Simon S, Han C, Wang F, Shaw J, Howes J, et al.
J Med Chem . 2019 Nov; 62(24):11232-11259. PMID: 31724864
The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC...
4.
Targeting WDR5: A WINning Anti-Cancer Strategy?
Aho E, Weissmiller A, Fesik S, Tansey W
Epigenet Insights . 2019 Jul; 12:2516865719865282. PMID: 31360909
WDR5 is a component of multiple epigenetic regulatory complexes, including the mixed lineage leukemia (MLL)/SET complexes that deposit histone H3 lysine 4 methylation. Inhibitors of an arginine-binding cavity in WDR5,...
5.
Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity
Aho E, Wang J, Gogliotti R, Howard G, Phan J, Acharya P, et al.
Cell Rep . 2019 Mar; 26(11):2916-2928.e13. PMID: 30865883
The chromatin-associated protein WDR5 is a promising target for pharmacological inhibition in cancer. Drug discovery efforts center on the blockade of the "WIN site" of WDR5, a well-defined pocket that...
6.
A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress
Nicolae C, Aho E, Choe K, Constantin D, Hu H, Lee D, et al.
Nucleic Acids Res . 2015 Mar; 43(6):3143-53. PMID: 25753673
Genomic instability, a major hallmark of cancer cells, is caused by incorrect or ineffective DNA repair. Many DNA repair mechanisms cooperate in cells to fight DNA damage, and are generally...
7.
The ADP-ribosyltransferase PARP10/ARTD10 interacts with proliferating cell nuclear antigen (PCNA) and is required for DNA damage tolerance
Nicolae C, Aho E, Vlahos A, Choe K, De S, Karras G, et al.
J Biol Chem . 2014 Apr; 289(19):13627-37. PMID: 24695737
All cells rely on genomic stability mechanisms to protect against DNA alterations. PCNA is a master regulator of DNA replication and S-phase-coupled repair. PCNA post-translational modifications by ubiquitination and SUMOylation...